Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of October 22, 2026, ABUS trades at $4.17 with a market cap of $857.80M and a P/E ratio of 5.41. ABUS moved -0.36% today. Year to date, ABUS is -12.37%; over the trailing twelve months it is -6.70%. Its 52-week range spans $2.71 to $5.45. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arbutus Biopharma buys back 46 million shares for $230 million in Dutch auction: Arbutus Biopharma repurchased 46 million common shares for cancellation at $5 each, totaling $230 million, or about 23% of shares outstanding as of Sept. 29, 2026. The offer was oversubscribed, and settlement is expected around Oct. 5.
| Metric | Value |
|---|---|
| Price | $4.17 |
| Market Cap | $857.80M |
| P/E Ratio | 5.41 |
| EPS | $0.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.45 |
| 52-Week Low | $2.71 |
| Volume | 129.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $181.72M |
| Net Income | $153.05M |
| Gross Margin | 0.00% |
ABUS analyst coverage data. Average price target: $0.00.